ADHD drugs and cardiovascular risk

被引：220

作者：

Nissen, SE ^{[1
]}

机构：

[1] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA

[2] US FDA, Drug Safety & Risk Management Advisory Comm, Rockville, MD 20857 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2006年 / 354卷 / 14期

关键词：

D O I：

10.1056/NEJMp068049

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1445 / 1448

页数：4

共 5 条

[1]

Food and Drug Administration, 2006, DRUG SAF RISK MAN AD

[2] Phenylpropanolamine and the risk of hemorrhagic stroke. [J].

Kernan, WN ;

Viscoli, CM ;

Brass, LM ;

Broderick, JP ;

Brott, T ;

Feldmann, E ;

Morgenstern, LB ;

Wilterdink, JL ;

Horwitz, RI .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (25) :1826-1832

[3] The relative safety of ephedra compared with other herbal products [J].

Kingston, RL ;

Borron, SW .

ANNALS OF INTERNAL MEDICINE, 2003, 139 (05) :385-385

[4] Report from the Cardiovascular and Renal Drugs Advisory Committee - US Food and Drug Administration; June 15-16, 2005; Gaithersburg, Md [J].

Nissen, SE .

CIRCULATION, 2005, 112 (13) :2043-2046

[5] Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder [J].

Wilens, TE ;

Hammerness, PG ;

Biederman, J ;

Kwon, A ;

Spencer, TJ ;

Clark, S ;

Scott, M ;

Podolski, A ;

Ditterline, JW ;

Morris, MC ;

Moore, H .

JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (02) :253-259

← 1 →